Detailed Narrative
Ventilator Business Resilience and Growth
Despite the implementation of new CMS National Coverage Determination (NCD) for Home Mechanical Ventilation, Viemed achieved its highest active ventilator patient count in history, reaching 12,635 patients by the end of June. The company added 546 net ventilator patients during Q2, representing approximately 4.5% sequential growth. This growth was supported by the second highest quarterly ventilator setup volume in company history and an improvement in usage compliance by over 25% compared to the prior year, demonstrating successful adaptation to the new NCD framework.
Diversified Expansion Across Service Lines
Beyond its core ventilation business, Viemed reported strong growth across other service lines. Q2 was a record quarter for PAP setups, with sleep therapy patients increasing approximately 5% sequentially and 44% year-over-year. Resupply patients served also saw significant growth, up approximately 10% sequentially and 47% year-over-year. The maternal health segment, benefiting from the Lehan acquisition, reached a new quarterly high for breast pump deliveries, with activity increasing approximately 9% sequentially.
Strategic Investments in Operational Efficiency and Sales
Viemed made deliberate investments to support continued organic growth and scale its operations. This included a revamp of the sales organization, adding a fourth division and refining leadership roles to enhance market coverage and clinical support. Operationally, the company implemented a new intake workflow partner, Tenor, which reduced PAP order qualification review time from days to less than an hour and shortened the incomplete order pipeline time by several days. The sleep resupply call center was also brought in-house to improve scalability.
Financial Performance and Capital Allocation
The company reported record revenue of $78.1 million in Q2, a 24% increase year-over-year. Gross profit was $45 million, representing a margin of 57.7%. Adjusted EBITDA was $13.7 million, with a margin of 17.6%, impacted by revenue mix and temporary maternal health costs. Operating cash flow for the quarter was $15.9 million, and free cash flow was $8.6 million. Viemed repaid $2.2 million of debt and repurchased 531,000 shares for $5.1 million, ending June with $10.7 million in cash.
Outlook and Confidence in Future Growth
Management expressed increased confidence in full-year revenue, raising the low end of guidance to $314 million-$320 million. The net CapEx outlook was lowered to 8.5%-10% of revenue, reflecting the growing contribution from less capital-intensive product and service revenue. While full-year adjusted EBITDA guidance was slightly revised to $64 million-$68 million, the company expects to deliver a full-year adjusted EBITDA margin of at least 20% and generate solid free cash flow, funding continued growth across its diversified platform.